Medicine and HealthNature Communications
A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants
Y. Du, R. Shi, et al.
Discover the groundbreaking research on h11B11, an ACE2-blocking monoclonal antibody that demonstrates exceptional efficacy in inhibiting SARS-CoV and SARS-CoV-2. Conducted by an expert team including Yanyun Du and Rui Shi, this study unveils promising therapeutic and preventive strategies against viral replication with minimal toxicity.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection
L. M. Coria, J. M. Rodriguez, et al.
Medicine and Health
A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
X. Zhang, H. Zhang, et al.
Medicine and Health
A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration
H. Ma, X. Zhang, et al.
Medicine and Health
A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
C. Kim, D. Ryu, et al.
